An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between "BR1017-1" and "BR1017-2" in Healthy Volunteers
Latest Information Update: 14 Feb 2023
Price :
$35 *
At a glance
- Drugs Atorvastatin/ezetimibe (Primary) ; Fimasartan (Primary)
- Indications Dyslipidaemias; Essential hypertension; Hypertension; Kidney disorders
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 06 Feb 2023 Status changed from recruiting to completed.
- 18 May 2022 New trial record